Results 61 to 70 of about 1,060,375 (218)

Identification of a Shiga toxin A‐derived peptide internalized into Gb3 receptor‐bearing cells via interaction with the Shiga toxin B subunit

FEBS Letters, EarlyView.
The process of internalization of the Shiga toxin A subunit via formation of a complex with the Shiga toxin B subunit, which specifically binds to the Gb3 receptor. The peptide is designed to act as a carrier of drugs into cancer cells. Here, we explored the potential of peptides derived from the catalytic A subunit of Shiga toxin (STxA) to be drug ...
Giulia Opassi, João C. Encarnação, Valeria Napolitano, Grzegorz Dubin, Grzegorz Popowicz, Karl Andersson, U. Helena Danielson   +6 more
wiley   +1 more source

Combination of drugs and carriers in drug delivery technology and its development

, 2019
Ying Du, Baoan ChenDepartment of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People’s Republic of ChinaAbstract: The development of drug-loading technology will bring new and rapid development to ...
Du Y, Chen B
core  

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. [PDF]

, 2008
BACKGROUND: New antimalarial regimens, including artemisinin-based combination therapies (ACTs), have been adopted widely as first-line treatment for uncomplicated malaria.
Njama-Meya Denise, Staedke Sarah G, Catherine Maiteki-Sebuguzi, Sarah G Staedke, Denise Njama-Meya, Moses R Kamya, Kristin Banek, Maiteki-Sebuguzi Catherine, Grant Dorsey, Yeka Adoke, Jagannathan, Prasanna, Dorsey, Grant, Talisuna, Ambrose O, Arthur Mpimbaza, Dorsey Grant, Ambrose O Talisuna, Rosenthal Philip J, Hasifa Bukirwa, Jagannathan Prasanna, Maiteki-Sebuguzi, Catherine, Rosenthal, Philip J, Tamara D Clark, Clark Tamara D, Yeka, Adoke, Banek, Kristin, Nzarubara Bridget, Staedke, Sarah G, Prasanna Jagannathan, Banek Kristin, Mpimbaza Arthur, Bukirwa, Hasifa, Nzarubara, Bridget, Philip J Rosenthal, Njama-Meya, Denise, Clark, Tamara D, Adoke Yeka, Mpimbaza, Arthur, Kamya Moses R, Bridget Nzarubara, Kamya, Moses R, Bukirwa Hasifa, Wabwire-Mangen Fred, Talisuna Ambrose O, Fred Wabwire-Mangen, Wabwire-Mangen, Fred   +44 more
core   +1 more source

Table1_New Hypoglycemic Drugs: Combination Drugs and Targets Discovery.docx

, 2022
New hypoglycemic drugs, including glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter 2 inhibitors (SGLT-2i), which brings more options for the treatment of type 2 diabetes ...
Liqin Tang (3984371), Lei Zhang (38117), Xiaojun Feng (231627), Xiayun Ni (12828140)   +3 more
core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants.

, 2009
Intermittent preventive treatment in infants (IPTi) is an effective and safe malaria control strategy. However, it remains unclear what antimalarials should be used to replace sulfadoxine-pyrimethamine (SP) when and where SP is no longer an effective ...
Chandramohan, Daniel, Mosha, Jacklin, Gosling, Roly, Greenwood, Brian, Cairns, Matthew, Gesase, Samwel   +5 more
core   +1 more source

Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. [PDF]

, 2010
BACKGROUND: There is renewed acknowledgement that targeting gametocytes is essential for malaria control and elimination efforts. Simple mathematical models were fitted to data from clinical trials in order to determine the mean gametocyte circulation ...
Bousema, Teun, Shekalaghe, Seif, Ghani, Azra C, Sauerwein Robert, Lucy Okell, Seif Shekalaghe, Shekalaghe, S., Colin Sutherland, Sutherland, Colin, Azra C Ghani, Ghani Azra C, Ghani, AC, Drakeley, Chris, Griffin, JT, Okell Lucy, Drakeley, C, Okell, L., Omar, Sabah, Sutherland Colin, Bousema, T., Sauerwein, R, Griffin, Jamie T, Drakeley Chris, Bousema Teun, Sawa, P., Jamie T Griffin, Shekalaghe, S, Drakeley, C., Omar, S., Okell, L, Sauerwein, Robert, Sawa, P, Shekalaghe Seif, Omar, S, Sauerwein, R.W., Sutherland, C, Ghani, A.C., Sawa, Patrick, Omar Sabah, Teun Bousema, Chris Drakeley, Sabah Omar, Robert Sauerwein, Okell, Lucy, Griffin, J.T., Bousema, T, Sutherland, C., Patrick Sawa, Sawa Patrick, Griffin Jamie T   +49 more
core   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Class of antiretroviral drugs and the risk of myocardial infarction

, 2007
BACKGROUND:We have previously demonstrated an association between combination antiretroviral therapy and the risk of myocardial infarction. It is not clear whether this association differs according to the class of antiretroviral drugs.
El-Sadr, W, De Wit, S, Phillips, Andrew, Friis-Moller, Nina, Weber, R, Reiss, Peter, Lundgren, JD, O. Kirk, W. M. El Sadr, Monforte, AD, R. Thiébaut, El-Sadr, Wafaa, R. Weber, Friis-Moller, N, N. Friis Møller, Law, MG, Lundgren, Jens D., Kirk, O, Thiebaut, Rodolphe, Fontas, E, Friis-Møller, Nina, De Wit, Stephane, Sabin, Caroline, P. Reiss, S. De Wit, A. N. Phillips, Sabin, CA, d'Arminio Monforte, Antonella, Law, Matthew G., Reiss, P, E. Fontas, Sabin, Caroline A., Lundgren, Jens D, DAD Study Grp, Monforte, Antonella d'Arminio, Phillips, Andrew N., J. D. Lundgren, Phillips, A, Fontas, Eric, M. G. Law, Weber, Rainer, C. A. Sabin, Kirk, Ole, A. d’Arminio Monforte, Law, Matthew   +44 more
core   +1 more source